Cubist Systematic Strategies LLC Purchases Shares of 28,663 Genelux Co. (NASDAQ:GNLX)

Cubist Systematic Strategies LLC purchased a new stake in shares of Genelux Co. (NASDAQ:GNLX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 28,663 shares of the company’s stock, valued at approximately $56,000.

Several other hedge funds have also bought and sold shares of the stock. Woodward Diversified Capital LLC grew its holdings in Genelux by 0.3% during the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after purchasing an additional 3,687 shares during the period. SageView Advisory Group LLC bought a new position in shares of Genelux in the first quarter worth about $121,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Genelux in the second quarter worth about $39,000. LifeSteps Financial Inc. boosted its stake in shares of Genelux by 50.2% in the second quarter. LifeSteps Financial Inc. now owns 66,536 shares of the company’s stock worth $130,000 after acquiring an additional 22,227 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Genelux by 2.4% in the first quarter. Vanguard Group Inc. now owns 1,023,030 shares of the company’s stock worth $6,578,000 after acquiring an additional 24,220 shares during the period. Institutional investors own 37.33% of the company’s stock.

Insider Buying and Selling

In other Genelux news, major shareholder Aladar Szalay sold 33,080 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $2.57, for a total transaction of $85,015.60. Following the sale, the insider now directly owns 599,821 shares in the company, valued at $1,541,539.97. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Over the last three months, insiders have sold 331,062 shares of company stock worth $736,831. Corporate insiders own 9.30% of the company’s stock.

Genelux Trading Down 3.1 %

NASDAQ:GNLX opened at $3.09 on Thursday. The company has a market capitalization of $106.15 million, a P/E ratio of -3.19 and a beta of -1.54. Genelux Co. has a 12 month low of $1.60 and a 12 month high of $20.62. The business’s 50-day moving average is $2.34 and its 200 day moving average is $2.76.

Genelux (NASDAQ:GNLX) last posted its earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). On average, research analysts forecast that Genelux Co. will post -0.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on GNLX shares. Roth Mkm started coverage on Genelux in a research note on Tuesday, August 27th. They issued a “buy” rating and a $10.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Genelux in a research note on Thursday, August 15th. Finally, Roth Capital raised Genelux to a “strong-buy” rating in a research note on Tuesday, August 27th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $22.33.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.